Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9337831 | 0.98 | TDP1 (0.43) | TDP1MEN1KMT2APOLBLMNA | |
| SCHEMBL3095348 | 0.98 | TDP1 (0.43) | TDP1MEN1KMT2APOLBLMNA | |
| SCHEMBL2124576 | 0.98 | TDP1 (0.43) | TDP1MEN1KMT2APOLBLMNA | |
| SCHEMBL14571178 | 0.93 | TDP1 (0.46) | TDP1MEN1KMT2APOLBLMNA | |
| SCHEMBL1645830 | 0.84 | — | — | |
| SCHEMBL21339941 | 0.82 | LMNA (0.48) | TDP1MEN1KMT2APOLBLMNA | |
| SCHEMBL827143 | 0.81 | POLB (0.48) | TDP1MEN1KMT2APOLBCA1 | |
| SCHEMBL13213048 | 0.80 | MEN1 (0.40) | TDP1MEN1KMT2APOLBPLA2G2C | |
| SCHEMBL16080807 | 0.80 | TDP1 (0.55) | TDP1MEN1KMT2APOLBCA1 | |
| SCHEMBL11327845 | 0.79 | TSHR (0.41) | TDP1LMNACYP3A4PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088725-B2 | Fragrance compositions and compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-20100132249-A1 | Fragrance Compositions and Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
| EP-2118249-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | Givaudan Nederland Services B.V. (NL) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008092678-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100132249-A1 | Fragrance Compositions and Compounds | H1-0, H1-10, H1-5 | TDP1 3227/4885MEN1 1171/4885KMT2A 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.